1. Home
  2. NGNE vs IGR Comparison

NGNE vs IGR Comparison

Compare NGNE & IGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$23.57

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Logo CBRE Global Real Estate Income Fund of Beneficial Interest

IGR

CBRE Global Real Estate Income Fund of Beneficial Interest

SELL

Current Price

$11.26

Market Cap

693.0M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
NGNE
IGR
Founded
2003
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
744.9M
693.0M
IPO Year
2014
2003

Fundamental Metrics

Financial Performance
Metric
NGNE
IGR
Price
$23.57
$11.26
Analyst Decision
Strong Buy
Analyst Count
10
0
Target Price
★ $77.88
N/A
AVG Volume (30 Days)
354.4K
★ 412.5K
Earning Date
11-12-2026
01-01-0001
Dividend Yield
N/A
★ 13.93%
EPS Growth
★ 0.93
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$15.93
$4.15
52 Week High
$43.66
$13.67

Technical Indicators

Market Signals
Indicator
NGNE
IGR
Relative Strength Index (RSI) 33.88 60.43
Support Level $16.88 $10.84
Resistance Level $29.16 $13.67
Average True Range (ATR) 1.99 0.20
MACD -0.13 -0.26
Stochastic Oscillator 29.31 42.86

Price Performance

Historical Comparison
NGNE
IGR

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About IGR CBRE Global Real Estate Income Fund of Beneficial Interest

CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.

Share on Social Networks: